A total of 46 eyes of 27 patients were treated with difluprednate for a mean of 16.4 weeks (range, 1-46 weeks). The mean age was 34 years (range, 6-63 years). Uveitis was anterior in 15 patients (56%), intermediate in 1 patient (4%), posterior in 1 patient (4%), and panuveitis in 10 patients (37%). Twenty-six patients had chronic disease. Prior to initiation of difluprednate treatment, 17 patients (63%) were using Pred Forte (prednisolone acetate, 1%), 8 patients (30%) were using generic prednisolone acetate, 1%, and 2 patients (7%) were not using topical steroids. All patients who were originally receiving Pred Forte or generic prednisolone acetate were switched because of persistent anterior chamber (AC) inflammation in at least 1 eye. The numbers of patients who displayed an elevation in IOP greater than or equal to 10, 15, and 20 mm Hg are shown in the Table, as are the numbers of patients who had a peak IOP greater than or equal to 30, 40, or 50 mm Hg.